Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2% - Time to Sell?
Atea Pharmaceuticals (NASDAQ:AVIR) saw its stock price drop by 2% to $4.02, with trading volume slightly below average. The company, a clinical-stage antiviral developer focusing on RNA viruses, reported an earnings per share miss at -$0.53. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with an average price target of $6.00, though analysts forecast a negative EPS for the current fiscal year.
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain
Institutional investors hold a significant majority, 65%, of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) and benefited most from the company's 21% stock price increase, which added US$56 million to its market capitalization last week. The top six shareholders account for 52% of the business, with FMR LLC, BlackRock, Inc., and BML Capital Management, LLC being the largest institutional holders. Insiders own 15% of the company, including CEO Jean-Pierre Sommadossi with 7.9% of shares, while the general public holds an 11% stake.
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Atea Pharmaceuticals presented its hepatitis C virus (HCV) strategy at the J.P. Morgan Healthcare Conference, focusing on its bemnifosbuvir/ruzasvir combination for "test-and-treat" models. The company emphasized the regimen's short duration, high potency, and low drug-drug interaction risk, especially for patients using proton pump inhibitors. Topline data for its Phase III C-BEYOND trial are expected mid-2026, with C-FORWARD results by year-end 2026.
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Atea Pharmaceuticals presented its hepatitis C virus (HCV) strategy at the J.P. Morgan Healthcare Conference, focusing on its bemnifosbuvir/ruzasvir (BEM/RZR) fixed-dose combination. This regimen is designed for expanded "test-and-treat" models, emphasizing its potency, short treatment duration, and low risk of drug-drug interactions. The company announced that enrollment is complete for its C-BEYOND Phase III trial with topline data expected mid-2026, while the C-FORWARD study results are anticipated by the end of 2026.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN)
This article summarizes recent analyst ratings for three healthcare companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR), and Penumbra (PEN). Boston Scientific received a maintained "Buy" rating from Bank of America Securities with a $120 price target, and a "Strong Buy" consensus. Atea Pharmaceuticals also maintained a "Buy" rating from William Blair, holding a "Moderate Buy" consensus. Penumbra was downgraded to "Hold" by Truist Financial and Piper Sandler, with a price target of $374.00, resulting in a "Moderate Buy" consensus.
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference
Atea Pharmaceuticals updated on its global Phase 3 program for hepatitis C (HCV) and introduced a new hepatitis E (HEV) antiviral candidate, AT-587, at the JPMorgan Healthcare Conference. The company expects Phase 3 HCV data mid-2026 and plans IND/CTA filings for AT-587 in Q2. Atea also reported a strong financial position with over $300 million in cash, projected to fund operations through early 2028.
Atea Pharmaceuticals to highlight strategic priorities for FY26
Atea Pharmaceuticals (AVIR) plans to present its strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The company finished 2025 with $301.8 million in cash and investments, providing a cash runway into 2027. Key upcoming milestones include Phase 3 topline results for its HCV regimen and the initiation of a Phase 1 clinical program for its HEV product candidate AT-587, both anticipated in 2026.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be available via live webcast and an archived version will be accessible on the company's website for at least 90 days. Atea Pharmaceuticals focuses on developing oral antiviral therapeutics for serious viral diseases.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals is set to present its 2026 strategic priorities at the J.P. Morgan Healthcare Conference, focusing on its Phase 3 program for Hepatitis C virus (HCV) treatment and the initiation of a Phase 1 clinical program for Hepatitis E virus (HEV). The company will highlight its potential best-in-class HCV regimen, with topline Phase 3 results expected mid-to-end 2026, and its new HEV product candidate, AT-587, addressing a significant unmet medical need. Atea ended 2025 in a strong financial position, with a cash runway extending through 2027.
New hepatitis C and E treatments move toward key human clinical trials in 2026
Atea Pharmaceuticals (NASDAQ: AVIR) announced its 2026 strategic priorities, including advancing its global Phase 3 program for a hepatitis C virus (HCV) treatment and initiating a Phase 1 study for a hepatitis E virus (HEV) treatment. The company expects topline results for its HCV C-BEYOND trial by mid-2026 and for the C-FORWARD trial by year-end 2026. Atea also highlighted its strong financial position with $301.8 million in cash and investments, providing a runway through 2027.
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026
Atea Pharmaceuticals provided an update on its strategic priorities for 2026, focusing on its global Phase 3 trials for a Hepatitis C virus (HCV) treatment regimen and initiating a Phase 1 clinical program for its Hepatitis E virus (HEV) candidate, AT-587. The company expects topline results from its North American HCV trial (C-BEYOND) by mid-2026 and from the ex-North America trial (C-FORWARD) by year-end 2026. Atea also reported a strong financial position with $301.8 million in cash and investments, providing a cash runway through 2027 to support its clinical developments in antiviral therapies.
Atea Pharmaceuticals Highlights 2026 Strategic Priorities
Atea Pharmaceuticals has outlined its strategic priorities for 2026, focusing on advancing its clinical programs for Hepatitis C virus (HCV) and Hepatitis E virus (HEV). The company ended 2025 with $301.8 million in cash and investments, providing a financial runway through 2027. Key milestones include upcoming Phase 3 readouts for its HCV treatment and the initiation of a Phase 1 program for HEV.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals is set to outline its strategic priorities for 2026 at the J.P. Morgan Healthcare Conference, focusing on its global Phase 3 program for Hepatitis C virus (HCV) treatment and advancing its Hepatitis E virus (HEV) program. The company expects topline results for its HCV regimen from two Phase 3 trials in mid-2026 and year-end 2026, respectively, and plans to initiate a Phase 1 study for its HEV candidate, AT-587, in mid-2026. Atea reported a strong financial position with $301.8 million in cash and investments at the end of 2025, providing a cash runway through 2027.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 7:30 a.m. PT. A live webcast of the presentation will be available on the company's website. The company specializes in developing oral antiviral therapeutics for serious viral diseases, leveraging a proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 15, 2026, at 7:30 a.m. PT in San Francisco, CA, with a live webcast available for those who cannot attend in person. The company specializes in developing oral antiviral therapeutics for serious viral diseases.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi, and other management team members will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live and archived on the company's website. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral antiviral therapies for serious viral infections.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live and archived on the company's website. Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral diseases.
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026
Atea Pharmaceuticals (AVIR) presents a potentially best-in-class HCV cure candidate, BEM/RZR, currently trading below its cash value with significant upside. This therapy offers the advantages of existing first-line treatments, including a single pill, no drug interactions, short treatment duration, and a high barrier to resistance. Phase 3 trial results are anticipated in 2026, which are expected to drive a strategic transaction for the company.
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs?
Atea Pharmaceuticals (AVIR) is advancing late-stage antiviral programs, most notably its Phase 3 hepatitis C trials for Bemnifosbuvir and Ruzasvir, with topline results expected in 2026. The company is actively expanding its pipeline with new hepatitis E candidates and maintains a strong cash position. These developments position Atea to potentially revolutionize the treatment landscape for viral infections.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has announced the completion of patient enrollment in its North American C-BEYOND Phase 3 trial for a hepatitis C virus (HCV) treatment. The trial, involving over 880 patients in the US and Canada, evaluates a fixed-dose combination of bemnifosbuvir and ruzasvir. Topline results for C-BEYOND are expected by mid-2026, while enrollment for a similar global trial, C-FORWARD, is anticipated to finish mid-2026 with results by year-end 2026.
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026
Atea Pharmaceuticals has completed enrollment for its C-BEYOND Phase 3 trial, involving over 880 patients in North America to evaluate a novel fixed-dose combination for HCV treatment, with topline results expected by mid-2026. Concurrently, the C-FORWARD trial is advancing outside North America, aiming for enrollment completion and results by year-end 2026. These trials represent the first global Phase 3 head-to-head comparisons of direct-acting antivirals for HCV, striving to offer a best-in-class treatment with short duration and minimal drug interactions.
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
Atea Pharmaceuticals has successfully completed patient enrollment for its North American Phase 3 clinical trial. This trial is evaluating a treatment regimen of bemnifosbuvir and ruzasvir for patients with the Hepatitis C Virus. The company announced this milestone completion, indicating progress in the late-stage development of its therapeutic candidates.
Atea Pharmaceuticals Completes Patient Enrollment in North
Atea Pharmaceuticals has completed patient enrollment in its North American Phase 3 C-BEYOND trial for hepatitis C virus (HCV) treatment, enrolling over 880 patients. Topline results for C-BEYOND are expected in mid-2026, while the C-FORWARD trial outside North America is also progressing with results anticipated by year-end 2026. This development marks a significant step towards developing a new, potentially best-in-class HCV treatment with short duration and low drug-drug interaction risk.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed patient enrollment in its C-BEYOND Phase 3 trial, involving over 880 treatment-naïve patients in the US and Canada for Hepatitis C. The trial evaluates a fixed-dose combination of bemnifosbuvir and ruzasvir, with topline results anticipated in mid-2026. The company aims to develop a best-in-class HCV treatment with short duration and low drug interaction risk to advance the standard of care and eradicate HCV.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed enrollment of over 880 treatment-naive patients in its C-BEYOND Phase 3 trial in North America for a hepatitis C virus (HCV) treatment. The trial evaluates a fixed-dose combination of bemnifosbuvir and ruzasvir, with topline results anticipated by mid-2026. Concurrently, the company is advancing enrollment for a similar Phase 3 trial, C-FORWARD, in other global regions, expecting its completion and results by year-end 2026.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals announced the completion of patient enrollment in its North American C-BEYOND Phase 3 trial for a hepatitis C virus (HCV) treatment. The trial, evaluating a fixed-dose combination of bemnifosbuvir and ruzasvir, expects topline results in mid-2026. A related global trial, C-FORWARD, is also progressing with results anticipated by year-end 2026, aiming to provide a best-in-class HCV treatment with short duration and low drug-drug interaction risk.
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals announced new modeling data supporting its bemnifosbuvir and ruzasvir fixed-dose combination as a potential best-in-class HCV treatment, showing near-complete viral inhibition and a modeled cure time of 7-8 weeks. These findings, along with resistance analysis and bioavailability data, will be presented at The Liver Meeting® 2025. The company will also host a virtual KOL panel to discuss the regimen's potential to advance HCV eradication.
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals (Nasdaq: AVIR) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025. Jean-Pierre Sommadossi, PhD, CEO and Founder, along with other management team members, will represent the company. A live webcast and archived recording will be available on Atea's investor relations website.
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET
Atea Pharmaceuticals announced that CEO Jean-Pierre Sommadossi and other management team members will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 10:00 a.m. ET. A live webcast will be available on the company's website, with an archived version accessible for 90 days. The announcement on November 19, 2025, led to a 3.28% increase in AVIR's stock price.
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals announced that its CEO and Founder, Jean-Pierre Sommadossi, and other management team members will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025. A live webcast of the presentation will be available on the company's website. Atea focuses on developing oral antiviral therapies for serious viral infections, with its lead program targeting HCV.
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals announced its Q3 2025 financial results and business updates, including progress in its global Phase 3 program for Hepatitis C Virus (HCV) treatment with bemnifosbuvir and ruzasvir, and the expansion into a new Hepatitis E Virus (HEV) development program. New data presented at The Liver Meeting 2025 supported the HCV regimen's efficacy and unique dual mechanism of action. The company also reported its financial position, highlighting $329.3 million in cash and a stock repurchase program.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript
Atea Pharmaceuticals, Inc. held its Q3 2025 earnings call, discussing significant progress in its Phase III HCV program, with enrollment on track and top-line results anticipated in mid to late 2026. The company also announced new research findings on bemifovir's dual mechanism of action and expanded its antiviral pipeline to include hepatitis E virus (HEV) with promising preclinical candidates. Despite missing EPS expectations, Atea maintains a strong balance sheet with $329.3 million in cash, providing a runway through 2027 to fund its programs.
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its Q3 2025 financial results and provided a business update, highlighting that patient enrollment for its global Phase 3 program for Hepatitis C Virus (HCV) treatment is on track, with topline results from the North America trial expected mid-2026. The company also announced new data supporting bemnifosbuvir's unique dual mechanism against HCV and the expansion of its antiviral pipeline with a new Hepatitis E Virus (HEV) development program. Financially, Atea reported $329.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and a net loss of $42.049 million for the quarter.
Atea (Nasdaq: AVIR) says HCV Phase 3 on track; C-BEYOND topline results mid-2026
Atea Pharmaceuticals reported Q3 2025 financial results, with its global HCV Phase 3 program, C-BEYOND and C-FORWARD, on track for topline results in mid-2026 and end of 2026 respectively. The company also announced a new HEV development program and presented new data supporting the dual mechanism of bemnifosbuvir. Atea finished the quarter with $329.3 million in cash and marketable securities.
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss
Atea Pharmaceuticals reported a larger-than-expected Q3 2025 EPS miss of -$0.53 against a forecasted -$0.42, yet its stock price rose by 3.25% in aftermarket trading. The company highlighted advancements in its hepatitis C (HCV) and E virus (HEV) treatment programs, including new data on bemnifosbuvir's dual mechanism of action and the expansion of its antiviral pipeline to address unmet needs in HEV, maintaining a strong cash position through 2027. Despite the earnings miss, investor optimism stems from these strategic initiatives and promising clinical development.
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals announced new modeling data supporting its fixed-dose combination (FDC) of bemnifosbuvir and ruzasvir as a potential best-in-class, short-duration treatment for hepatitis C virus (HCV) infection. The data, to be presented at The Liver Meeting® 2025, suggest near-complete viral inhibition and a modeled cure time of 7-8 weeks, reinforcing previous Phase 2 results. The company will also present resistance analysis and bioavailability data, highlighting the regimen's efficacy, high barrier to resistance, and flexibility with food or other medications.
Atea Pharmaceuticals to Host Third Quarter 2025 Financial
Atea Pharmaceuticals announced it will host a conference call and audio webcast on November 12, 2025, to discuss its financial results for the third quarter ended September 30, 2025, and provide a business update. Investors can register to access the live conference call or find the webcast in the Investor Relations section of the company's website. The call will cover the company's focus on developing oral antiviral therapies for serious viral infections and its lead program for treating HCV.
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
Atea Pharmaceuticals announced it will host a virtual Key Opinion Leader (KOL) event on November 13, 2025, to discuss various topics related to hepatitis C virus (HCV), including patient population, diagnosis, treatment, and public policy. The event will feature several HCV KOLs and company management, who will also discuss the HCV commercial market opportunity and Atea’s global Phase 3 clinical development program for bemnifosbuvir and ruzasvir. A live Q&A session will follow the formal discussion.
Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock
Insiders at Atea Pharmaceuticals, Inc. have seen a positive return on their investments over the last 12 months, with US$5.40m worth of stock now valued at US$6.12m. The largest insider purchase was made by Bradley Radoff for US$5.3m worth of shares at a price above the current market value, suggesting confidence in the company's future. Overall, insider buying significantly outweighed selling, indicating a strong insider appetite for the stock despite recent price fluctuations.
Antiviral Drug Developer Atea Pharmaceuticals to Present Latest Pipeline Updates at Morgan Stanley Conference
Atea Pharmaceuticals (Nasdaq: AVIR) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, where its management team will hold a fireside chat on September 9, 2025, at 1:05 p.m. ET in New York. Investors can access the presentation via live webcast on the company's investor relations website, with an archived version available for at least 90 days. The company, a clinical-stage biopharmaceutical firm, focuses on developing oral antiviral therapeutics for serious viral diseases.
Atea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40m
Insiders at Atea Pharmaceuticals, Inc. have significantly increased their holdings over the last year, with total insider purchases amounting to US$5.40 million. A large portion of this came from insider Bradley Radoff, who bought US$5.3 million worth of shares, suggesting confidence in the company's future despite the stock price being lower than his purchase price. Insiders currently own 14% of the company, indicating some alignment between management and shareholders.
Atea Pharmaceuticals announces continued advancement of global Phase 3 HCV program
Atea Pharmaceuticals announced the continued advancement of its global Phase 3 HCV program with the dosing of the first patient in the C-FORWARD trial, which is evaluating a combination regimen for hepatitis C treatment. This trial, conducted outside North America, compares bemnifosbuvir and ruzasvir against sofosbuvir and velpatasvir. Atea had previously initiated the C-BEYOND Phase 3 trial in the US and Canada in April 2025.
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group
Latham & Watkins LLP advised Atea Pharmaceuticals, Inc. in an agreement with the Radoff-JEC Group. The agreement led to the appointment of Howard H. Berman, Ph.D. to Atea's Board of Directors and the Radoff-JEC Group's withdrawal of its director candidates. This resolution was facilitated by Latham & Watkins' shareholder activism defense and public company representation teams.
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
Atea Pharmaceuticals outlined several strategic actions to enhance shareholder value, including engaging an investment bank to explore partnerships for its Phase 3 HCV program. The company also reduced its workforce by 25% for an estimated $15 million in cost savings through 2027 and appointed Arthur S. Kirsch as an independent director to its Board. These measures aim to optimize operations and strengthen governance ahead of its 2025 Annual Meeting of Stockholders.
Atea offloads a quarter of its workforce, gears up for phase 3 HCV trials
Atea Pharmaceuticals has laid off 25% of its workforce this year while preparing to launch two phase 3 trials for its hepatitis C cocktail, bemnifosbuvir and ruzasvir, after successful phase 2 results. The company aims to disrupt the global HCV market, which it values at $3 billion annually, and has enlisted Evercore to explore strategic partnerships for its phase 3 program. These efforts align with Atea's goal to achieve $15 million in savings through 2027 and extend its cash runway into 2028.
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
Atea Pharmaceuticals announced successful Phase 2 trial results for its experimental hepatitis C combination drug, paving the way for a Phase 3 study early next year. The regimen achieved a 98% sustained virologic response and aims to offer a more convenient treatment option for the growing younger hepatitis C patient population. This positive news comes as a crucial win for Atea, which previously faced setbacks with its COVID-19 treatment and a declining stock price.
Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR)
Atea Pharmaceuticals (NASDAQ: AVIR) shares fell significantly after its antiviral therapy, bemnifosbuvir, failed to meet the primary endpoint in a global Phase 3 trial for COVID-19 treatment. The drug's setback led to an approximate 24% drop in Atea's stock.
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Atea Pharmaceuticals announced that its oral COVID-19 treatment, bemnifosbuvir, failed to meet the primary endpoint in the late-stage SUNRISE-3 trial, which aimed to reduce hospitalization or death in high-risk patients. The company attributed the failure to the "constantly evolving" nature of COVID-19 and a trend toward milder disease. Atea Pharmaceuticals will now focus on developing the combination of bemnifosbuvir and ruzasvir for hepatitis C, having recently reported positive Phase 2 data for this indication.
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
Atea Pharmaceuticals will host a conference call and audio webcast on August 7, 2024, at 4:30 p.m. ET, to report its second quarter 2024 financial results and provide a business update. The financial results will cover the quarter ended June 30, 2024. Investors can access the event via the company's website or by registering for the telephone conference call.
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals announced that its CEO and Founder, Jean-Pierre Sommadossi, PhD, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation, focusing on the clinical-stage biopharmaceutical company's oral antiviral therapeutics for serious viral diseases, will be webcast live and archived on the company's investor relations website. Atea Pharmaceuticals specializes in developing oral antiviral therapies for serious viral infections including COVID-19 and hepatitis C.
